← All deals

Galvanize Therapeutics, Inc.

BiotechnologyBiotechnologyMedical TechnologyPEF Ablation
📍 Redwood City, CA, United States• Founded 2015
StreetZero Signal 83
Be the first to signal interest

About Galvanize Therapeutics, Inc.

Galvanize Therapeutics, Inc. is a commercial-stage medical technology company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease. It develops non-thermal, non-pharmacologic interventions using short electrical pulses to target pathologic cells, including the Aliya® PEF platform for solid tumors and RheOx® therapy for chronic bronchitis. The company aims to become a global leader in medical technology innovations that drive biologic processes to treat a range of diseases.

LATEST FUNDINGPrivate Placement
$136.2M
Announced 2026-11-18
TOTAL RAISED$291.01M
🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Galvanize Therapeutics, Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Raised $100M oversubscribed Series C in 2025 led by Sofinnova Partners to expand commercial footprint and advance Aliya PEF and RheOx therapies.
  • Closed $130M oversubscribed Series D in 2026 led by HealthQuest Capital to accelerate commercial growth.
  • Platform uses non-thermal short-duration electrical pulses to destabilize cellular pathologic processes.
  • Total funding exceeds $291M with backing from Fidelity, Apple Tree Partners and others.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account